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balance. On the contrary, all the patients are still on Milvane. In 
conclusion, the anticonceptyional treatment with Milvane is not 
hithetto resulted to be able to worsen the metabolic balance in 
diabetic patients. Further studies are required during more 
prolonged treatment to dmw any definitive conclusions. 
137. Predictive value of tbe active renin assay for 
tbe early diagnosis of ectopic pregnancy 
L. Cedard, Th.M. Mignot, K. Meunier, A. Maria1, A Guichard, 
P. Boyer, I.R. Zorn 
U. 166 INSERM and Maternite Baudelocque, Paris; 1 Hopital 
Villeneuve-St-Georges. France 
The increasing frequency of ectopic pregnancy and the need of 
its early diagnosis have focused our interest on the research of 
biochemical markers. We have previously studied the profile of 
hCG, progesterone, and renin in fertile cycles after IVF-ET or 
GIFT and shown that his last parameter did not increase in 
ectopic pregnancies contrary to evolutive or abortive intrauterine 
pregnancies. After having established the hormonal value in the 
plasma of 99 spontaneous ongoing pregnancies between the 4th 
and 10th week of amenorrhea we have compared them to the 
values observed in 21 ectopic and 20 abortive pregnancies. The 
hCG levels are significantly higher in ongoing pregnancies but 
there is no statistically significant difference between abortive and 
ectopic gestation. The progesterone levels are significantly lower 
in ectopic pregnancies than in intrauterine gestation but are not 
really discriminant. The best parameter appears to be low active 
renin immunoradiometric assay (pasteur Diagnostic). The 
difference between ectopic pregnancy and evolutive or abortive 
intrauterine gestations is highly significant, the highest value 
corresponding to the 25th pecentile of normal values. The 
association of low hCG « 15000 Ul/ml) and low active renin (~ 
30 nglml) seems to be highly predictive of the ectopic pregnancy. 
The renin angiotensin system has an important role in the 
process of implantation, but an early signal could also be 
transmitted by the implanted embryo to the corpus luteum. 
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138. Tbe errect of polycblorinated Bipbenyls (PCB) 
on estradiol syntbesis of buman cumulus cells 
K. van der Ven, H. van der Ven, A. Thiebold, S. AI-Hasani, U. 
Wagner, K. Diedrich, and D. Krebs 
Department of Obstetrics and Gynaecology. University of Bonn. 
Bonn. Fed. Rep. of Germany 
Chlorinated hydrocarbons, E.G. PCBs, DDT, HCB, can be 
found in various body tissues and fluids. In human follicular fluid 
(n=10) we could determine the following concentrations of 
various PCB congeners (Ballschmitter nO 15, 118, 138, 153. 169, 
180) on estradiol synthesis of human cumulus cells was 
investigated. Cumulus cells were collected in an IVF programme 
and cultured in a modified Ham's FlO medium supplemented with 
5% fetal calf serum and 50 nglml 17P testosterone (cell 
concentration: 25000/ml. The PCB congeners were added in 
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concentrations between 0.1 and 1000 nglml. The concentration of 
estradiol was determined in the cell free supernatants after a 24 
hour culture period. All PCB congeners induced a dose dependent 
reduction of estradiol synthesis by human cumulus cells. The 
various PCB congeners showed different biological activities in 
regard to the inhibitory effect on estradiol secretion. A decrease of 
estradiol secretion could already be observed in PCB 
concentrations that correspond to the average load of human 
follicular fluid. 
139. Endocrine and immunological cbances in 
women witb cbronic wood preservative exposition 
I. Gerhard, M. Derner, B. Runnebaum 
Department of Gynaecological Endocrinology. Women's 
Hospital. University of Heidelberg. Heidelberg, F R.G. 
The influence of environmental pollution on human 
reproductive performance is unknown. The toxicity of 
organochlorine compounds (OC) was recongized following 
accidental poisoning. In animal studies OC administration 
resulted in a reduced number of pregnancies, and increased number 
of stillbirths. In the subsequent generation reduced fertility and 
chances in the menstrual cycle were noted. Wood preservatives 
containing various toxic OC are frequently used in industrialized 
states. Therefore it was the aim of this study to measure the 
pesticides pentachlorophenol (PCP) and 
gammahexachlorocyclohexane (Lindane, L) in women with 
hormonal disorders. In 22 out of 90 women examined elevated 
OC concentrations were found by capillary chromatography and 
masspectroscopy. PCP serum levels above 25 J.1g/l were judged 
elevated, as were L blood levels above 100 ngll. Elevated 
concentrations were found in 8 fertile women (6 of them with 
repeated abortions, aged 26-33 years), 8 women (aged 16 - 35 
years) with menstrual disorders and androgenisation symptoms, 
and 6 women (aged 42 - 56 years) with climacteric symptoms. 
The source of emmission was identified in the residence of each 
patient, the duration of exposure ranged from 2 to 20 years. 16 
women presented with adrenocortical malfunction (7 with 
hyperandrogenemia and 9 with partial adrenocorticoinsufficiency), 
15 with immunological disorders, 6 with thyroid gland 
dysfunction (1 with hyper- and 5 with hypothyroidism) and 3 
with luteal phase insufficiency. After elemination of the causative 
noxae and immunologic stimulation, blood OC concentrations 
decreased and the patients' physical conditions improved. 
menstruation normalized and, in case of conception, pregnancies 
resulted in healthy babies. On the basis of our data OC influence 
various hormonal systems including the adrenal and thyroid 
glands and reduce cellular immunity. Therefore an exact 
evaluation of environmental pollutions should be included in the 
endocrinological work-up of the patients with hormonal disorders 
and reproductive failure. 
140. Atrial natriuretic peptide (ANP) and 
progesterone in ovarian follicluar fluid 
E.A.P. Steegers, M. van Heeswijk, I.M.G. Hollanders, H.W. 
10ngsma, and P.R. Hein 
Department of Obstetrics and Gynaecology. University Hospital 
Nijmegen. The Netherlands 
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Synthesis and scretion of ANP is not confined to the heart, 
but has been shown to be present in other tissues too. ANP is 
known to affect steroidgenesis in the ovary. 
The aim of our work was , to assess the possibilities that a -
the human ovary is a source of ANP secretion as well and b -
ovarian ANP stimulates progesterone secretion. 
We investigated ANP as well as progesterone concentrations 
in preovulatory ovarian follicular fluid and in plasma from 15 
women in an in vitro fertilization programme. In twelve of them, 
follicular fluid was pooled before analysis; follicular fluid of three 
women was collected separately per follicle. 
In all women detectable ANP immunoreactivity was found in 
ovarian follicular fluid (range 3.3 - 60.1 pg/ml). Follicular fluid 
concentrations were low in all but one woman who demonstrated 
a higher ANP level in follicular fluid than in plasma. Follicular 
ANP and progesterone concentrations were not significantly 
correlated. These preliminary results suggest that the ovary could 
well be a site of ANP secretion. If and how ovarian ANP activity 
affects progesterone secretion remains as yet unknown. 
141. Plasma melatonin levels in the spontaneous 
female cycle, during the intake of oral contraceptive, 
under treatment with gonadrotropins, and in early 
pregnancy 
R. Zimmermann, T. Delfs, S. Baars, M. Schuhmacher, and F.A. 
Leidenberger 
Institute for Hormone and Fertility Reserach. Hamburg. Fed. 
Rep. of Germany 
We have examined the influence of endogenous and 
exogenous sex steroid hormones on the melatonin (MT) 
production pattern in women. Blood samples were dra~n at 4-
hourly intervals over a period of 24 hours and dady MT 
production was calculated from the area under the ~T 
concentration time curve (AUC). Eight volunteers were studied 
on the fourth day of the menstrual cycle, the day before 
luteininzing hormone (LH) surge, the day of LH surge, and in the 
midluteal phase. The AUCs were 555.5 +/- 89.3, 642.7 +/-
149.0, 486.6 +/108.5, and 457.2 +L 69.6 units (mean +/- S.E.) 
respectively (differences n.s.). The intake of oral contraceptives 
was not accompanied by any significant changes in MT 
production, neither concerning the time point of intake nor the 
gestagen content of the preparation. The effect of human 
menopausal gonadotropin (HMG) and human chorionic 
gonadotropin (HCG) on MT levels could be studied in 6 women. 
The MT AUCs for the 3rd day after onset of menstrual bleeding, 
on the day when estradiol exceeded 600 pg/ml, and 7 days after 
10,000 u HCG were 889.4 +/- 169.2, 885 +/- 152.6, and 773.5 
+/- 220.5 units respectively (differences n.s.). In addition, the MT 
levels in the 10th week of pregnancy were ivenstigated in 9 
women and the AUC obtained was 741.0 +/- 110.3 units. In 
conclusion, an influence of sex steroid hormones on the pineal 
activity could not be detected. This however, does not exclude a 
relevance of MT in human reproduction. Possibly, it could act as 
a chronobiologic transmitter, thus conditioning, the CNS for 
optimal reproductive performance. 
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142. Reduced pulsatile LU secretion in follicular 
phase and impaired progesterone levels in luteal 
phase of normally menstruating women 
P. Inaudi, M. Germondl , V. De Leo, S. Baldini, N. D'Antona 
Dept. of Obstetrics and Gynecology. University of Siena. 
I Department of Obstetrics and Gynecology, CHUV. CH-IOII 
Lausanne. Switzerland 
Since luteal cells originate from the granulosa-theca cell 
complex and the increase of granulosa cell number is a 
gonadotropin-related mechanism, the hypothalamic c.ontrol of 
gonadotropin release during follicular phase (FP) seems tmportant 
for a valid corpus luteum development 
We studied 6 women of 25-37 years and a cycle length of 
30+/-2 days, showing progesterone (P) levels < 2Onmol/l- group 
1) and 6 healthy age-matched women taken as control (p>20 
nmol/l - group 2); blood samples were taken every 10 min for 6 
hours from 8 a.m. in early FP (days 3-6) for LH determination 
(IFMA method, Cyberfluor, POL YMED, FI, Italy). Furthermore 
a basal blood sample was obtained every 2-3 days throughout 
luteal phase (LP) for P evaluation (Sorin Kit, Saluggia, VC, 
Italy). The characterization of the pulsatile LH patterns was 
performed by DETECT programme (D. Rodbard, NIH, USA) 
using a false peak detection level of 1 %. 
A significant reduction of both basal levels and frequency of 
the pulsatile LH secretion was found in group 1; a secretory event 
happens every 120 min or more (50-60 min in the conf:Tol group) 
with adequate amplitude. Across the LP the P levels 10 group 1 
are generally lower than 20 nmol/l, with a range of 4.5-7.4 
nmol/l (24.6-46.8 nmol/l in group 2). 
The present results show that low P levels during LP can be 
associated with a decreased LH pulse frequency in follicular phase 
suggesting that the timing of LH pituitary discharge could play 
an important role for an adequate development of corpus luteum. 
143. Impaired corpus luteum function associated 
with mid-luteal long acting GnRU-analogue 
administration 
A. Golan, A. Herman, R. Ron-El, Y. Soffer, H. Nachum, and E. 
Caspi 
IVF unit. Department of Obstetrics and Gyaecology. Assaf 
Harofe Medical Centre. Tel Aviv University,lsrael 
Nine spontaneous pregnancies associated with mid-luteal 
administration of long acting GnRH-analog are reported. A 
definite impaired function of the corpus luteum was demonstrated 
by the low progesterone and estradiol levels despite rising levels 
of HCG. Three of these early pregnancies were supplemented and 
2 ended as pre-clinical abortions. The other 6 were treated with 
progesterone and 3 of them with additional estradiol valerate. Of 
these one ended as a blighted ovum and the rest uneventfully at 
term.' It seems that the occurrence of a spontaneous pregnancy in 
cycles in which GnRH analog is given i~ the luteal phase are. not 
a rare phenomenon. It is even pOSSible that the transient 
stimulatory phase following its administration may facilitate 
implantation. Early diagnosis and close hormonal monitoring are 
strongly recommended for evaluation of the corpus luteum 
function and adequate supplementation. 
144. Triggering 
healthy subjects 
ovulation by progesterone in 
S. Zalanyi jr. 
A. Szent-Gyorgyi University School of Medicine. Szeged. 
Hungary 
Five regularly menstruating healthy subjects were monitored 
by ultrasound folliculometry and daily blood sampling during the 
follicular phase of a control and a treatment cycle. These 
procedures were repeated a second time daily when the follicle 
reached 16 mm diameter until ovulation was confIrmed. In the 
~ent cycle progesterone (P) 10 mg in oil was injected i.m. 
to mduce ovulation when the follicle attained 18 mm which was 
about two days prior to the expected day 'of ovulation. The 
administration of P was guided by ultrasound folliculometry 
alone. Blood samples were processed for estimation of serum 
estradiol (E), P and luteinizing hormone (LH) later on. All the 
subjects ovulated both in control and treatment cycles as 
demonstrated by folliculometry, LH peak and luteal pha~ P 
values. LH peak followed P adminstration uniformly by 24 hours 
and was advanced by 36 hours on average (range 12-48 hours) 
shortening the follicular phase from 12.8 to 11.3 days. E2 peak 
valu~s were lower~ but LH peak and luteal phase P levels 
remamed the same 10 the treatment cycle. These observations 
provide evidence that exogenous P may initiate ovulation in 
heal.thy subjects mimicking all events (drop of E2, LH peak and 
folhcular rupture) thought to be characteristic of the 
physiological process itself. They further substantiate the theory 
that P may be (one of) the trigger(s) of ovulation. 
145. Opioid antagonism prevents 
response in pre-menstrual syndrome 
the placebo 
J.H. Schagen van Leeuwen, E.R. te Velde, H.P.F. Koppeschaar, 
J.H.H.Thijssen, W.J. Kop, J.M. van Ree, and A.A. Haspels 
University Hospital Utrecht. The Netherlands 
A double blind placebo controlled study with nalmefen an 
oral opioid antagonist, was perfomed to assess the rol~ of 
endogenous opioids in the pre-menstrual syndrome (PMS). 
Twe~ty-~ women,. whose diagnosis ofPMS was confmned by 
longltudmal prospectIve monitoring of complaints, participated. 
Nalmefen (n=12) ~d placebo group (n=II), were comparable for 
age, body mass mdex, length of cycle, parity, marital and 
employment status. Placebo was administered throughout the 
menstrual cycle, while nalmefen group started active medication 
on day 12, after taking placebo in the follicular phase. in the 
placbo group, the highly significant fluctuation of PMS 
symptoms observed during the selection (1,2) and pre-treatment 
(3,4) cycles, completely disappeared in the "treatment" (5,6) 
cycles. In contrast, .symptoms remained cyclic during nalmefene 
treatmenL Concomitantly, to acquire indirect evidence of central 
opioid activity on luteinizing hormone releasing hormone 
(LHRH), and to assess the effect of nalmefene on menstrual cycle 
related. hormones, plasma levels of p-endorphin, LH, FSH, 
oestradiol and progesterone (P) were measured on day 12,22. and 
~ o~ cycle ~,5, and ~. Both in the placebo and nalmefen group, a 
slgmfIcant 10crease 10 p-endorphin occurred, (p<0.03). In the 
placebo group LH, FSH, oestradiol and P decreased whereas 
following nalfene these levels increased. Mid-luteai P levels 
differed signifIcantly: p<O.01. 
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~hese results suggest that the placebo response in PMS is 
mediated by endogenous opioids. Antagonism of these opioids 
prevents the placebo induced amelioration in PMS. The 
mvolvement of central opioid activity, through LHRH, is 
reflected by an increase in sex hormones with nalmefene, while 
on placebo the hormone proflle attenuated? Also the increase in 
peripheral f}-endorphin is difficult to explain other than as a 
central event. Placebos, when perceived as remedy, apparently 
have pharmacological properties. 
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therapy (Symposium Sandoz) 
146. Hyperprolactinemia treated with modified 
release bromocriptine (parlodel SRO) 
A. Luizzi, D. Dallabonzana, R. Cozzi, S. Strada, G. Oppizzi, 
P.G. Chiodini, and I. Lancranjan1 
fivision of Endocrinology. Ospedale Niguarda. Milan. Italy; 
Department of Neuroendocrinology; Sandoz Ltd .• Basel. 
Switzerland 
Parlodel SRO (slow release oral) is a new formulation of 
brom~ri~tine that allows to obtain retarded peak plasma levels 
and a SignifIcantly longer half life than the standard preparation of 
Parlodel; these pharmacokinetcs prompted us to evaluate its 
effectiveness during acute and chronic administration in patients 
with pathological hyperprolactinemia (PHP). 
.Acute ~tudies. A single dose of 5 mg SRO given to 13 
patients With PHP determined a signifIcant reduction of PRL 
levels from the 2nd up to the 24th hour (Baseline 1033 ± 346 
ng/ml; mean ± SE; nadir: 193 ± 3 ng/ml; 24 hours: 359 ± 81 
ng/ml). 
Chronic studies in a double blind randomized study of one 
month performed in 20 patients, 5 or 10 mg of SRO given as a 
single daily adminstration proved as effective in lowering PRL 
levels as the equivalent doses of Parlodel given b.Ld. In more 
prolonged studies SRO, given in a single daily adminstration at 
doses ranging from 5 to 10 mg/day for a mean period of 7.5 
month~ (range 0.5 - 18) to 8 untreated PHP patients, determined a 
reductIon ofPRL levels (from 1352.2 ± 901 ng/ml to 40 ± 18.9 
ng/ml; p < 0.01), a recovery of the gonadal function in 3/8 and a 
shrinkage of the macroadenoma in 4/5. In other 14 PHP patients 
shifted to SRO from a previous treatment with equivalent doses 
of Parlodel, PRL levels showed a further signifIcant decrease from 
56.4 ± 8.6 ng/ml to 24.7 ± 5.5 ng/ml (p<O.OI). Gonadal 
function, impaired before treatment in all these patients, had 
normalized in 12/14 during Parlodel and also in the two 
remaining patients during SRO. Eight out of 10 macroadenomas 
shrank during Parlodel; a frurther reduction of the tumor occurred 
in 3 of them during SRO. Only 2/27 patients complained of side 
effects during SRO treatment. 
We conclude that SRO is a further advancement in the 
pharmacological approach by dopamine agonists to PHP as it 
allows goor clinical results by a once a day adminstration. 
(Study supported by Special Programme of the National Research 
Council "Oncology;', Grant nO 88.00723.44) 
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